Cite
HARVARD Citation
Hernandez, M. et al. (n.d.). 536 RANIDO trial: Racotumomab-alum vaccine, Nimotuzumab or Docetaxel as switch maintenance therapy for advanced NSCLC. European journal of cancer. pp. S116-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Hernandez, M. et al. (n.d.). 536 RANIDO trial: Racotumomab-alum vaccine, Nimotuzumab or Docetaxel as switch maintenance therapy for advanced NSCLC. European journal of cancer. pp. S116-. [Online].